Skip Navigation
Skip to contents

Intest Res : Intestinal Research

Search
Advanced Search
IMPACT FACTOR
mobile search button mobile menu button
How effective is transabdominal ultrasonography in predicting the relapse of Crohn’s Disease?
Published online: February 6, 2024


  • 367 Views
  • 0 Download
  • 0 Crossref
  • 0 Scopus
Full Article

Effectiveness of transabdominal ultrasonography in predicting clinical relapse of Crohn’s disease
Intest Res. 2023;22(1):82-91

Crohn's disease (CD), primarily affecting the ileum and colon, poses challenges in managing and predicting disease activity. Despite various treatments, many CD patients experience relapses and about 50% develop complications. Identifying patients nonresponsive to treatments is crucial. Transabdominal ultrasound (US) has emerged as a promising, non-invasive, and cost-effective diagnostic tool for CD, offering accuracy in disease management and patient care.
The present study investigates the efficacy of transabdominal US in predicting clinical relapse in CD patients. Utilizing a unique US-based scoring system, the research analyzes a retrospective patient data. The study included 73 patients who were followed for a median duration of 1,441 days, during which various clinical outcomes were observed. The results demonstrate a clear correlation between high US-CD scores and increased relapse risk, offering a non-invasive, effective tool for anticipating disease progression and guiding treatment strategies.

  1. Of the patients, 16.4% experienced clinical relapse, 9.6% required endoscopic balloon dilation (EBD), 58.9% needed enhanced treatment, and 20.5% underwent surgery.
  2. High US-CD scores are strongly linked to CD relapse. In multivariate analysis, US-CD was significantly associated with both clinical relapse (P=0.038) and the need for enhanced treatment (P<0.01).
  3. The area under the ROC curve with US-CD was 0.77 for predicting clinical relapse (cutoff value=11), 0.81 for the need for EBD (cutoff value=11), and 0.74 for requiring enhanced treatment (cutoff value=6), respectively.
  4. Patients with a US-CD score of 11 or higher had a significantly higher risk of clinical relapse and need for EBD within 5 years, while those with a score of 6 or higher were more likely to require enhanced treatment in the same timeframe.
Read more about the effectiveness of transabdominal ultrasonography in predicting clinical relapse of CD.

Best regards,

Related articles
Intest Res : Intestinal Research
© Korean Association for the Study of Intestinal Diseases.
Close layer
TOP